Tecentriq® (atezolizumab): A new identified risk of severe cutaneous adverse reactions

A Dear Healthcare Professional Letter has been issued by Hoffman-La Roche to update healthcare professionals on a new identified risk of severe cutaneous adverse reactions (SCARs) associated with the use of Tecentriq®. Based on the totality of evidence in a recent analysis, SCARs are now considered to be an identified risk for atezolizumab. Consequently, the local Tecentriq® package insert will be updated to reflect the safety information on this risk. Healthcare professionals are advised to refer suspected cases of SCARs to a dermatologist for further diagnosis and management, to withhold atezolizumab from patients with suspected Stevens Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) and to permanently withdraw atezolizumab for any grade confirmed SJS or TEN. Caution is advised when considering the use of atezolizumab in a patient who has previously experienced a severe or life-threatening skin adverse reaction on prior treatment with other immune-stimulatory anticancer agents. Please refer to the letter for details.
Healthcare professional, Industry member, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Nov 2020

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg/, and follow the procedures below to access the MOH Alert system.

Step 1: Scroll down to the bottom navigation panel of the HPP web page. Under the Healthcare Professionals section, expand the dropdown option for ‘Healthcare Professional Portal’ and select your profession. You will be redirected to the specific HPP web page to log in.

Step 2: Click on the Restricted Content icon on the left panel of the web page and log in via SingPass.

Step 3: Click on the MOH Alert icon under the ‘Applications’ section.

Step 4: Click on the Drug Alert tab to view the DHCPLs.